Antipsychotic Drugs Market by Therapeutic Class (First-Generation and Second-Generation), Application (Schizophrenia, Dementia, Bipolar Disorder, Depression, and Others), and Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies): Global Opportunity Analysis and Industry Forecast, 2021–2030
- ALL4676942
- 187 Pages
- September 2021
- Diagnostic and Biotech
Antipsychotics, also known as neuroleptics, are a class of psychotropic medication primarily used to manage psychosis, principally in schizophrenia and also in a range of other psychotic disorders. Antipsychotics are also the mainstay together with mood stabilizers in treatment of bipolar disorder.
The key factor driving the market growth include rise in awareness and focus on mental illness, increase in depression due to stressed lifestyle, and rise in number of mental hospitals. According to the World Health Organization (WHO), in 2018, globally more than 300 million individuals suffered from depression. The considerably large number of people suffering from mental stress increases demand for antipsychotic drugs. However, side effects such as weight gain, increasing cholesterol levels, and risk of diabetes caused due to antipsychotic drugs hamper the market growth.
Government initiatives for mental illness are expected to boost growth of the global antipsychotic drugs market, offering expansion opportunities for market competitors. For instance, in 2017, the Centers for Medicare and Medicaid introduced the psychiatric Collaborative Care Model (CoCM) and Behavioral Health Integration (BHI) under the Chronic Care Management (CCM) services initiative.
Rise in prevalence of mental health disorders, such as schizophrenia and bipolar disorder amongst the population is a major growth driver for the market. As per the Anxiety and Depression Association of America, Anxiety disorder is the most common mental illness in the U.S, affecting 40 million adults aged 18 and older, or 18.1% of the population every year. Nearly one-half of those diagnosed with depression are also diagnosed with an anxiety disorder.
World Health Organization (WHO) has recommended mental health action plan to promote mental health and preventing mental disorders in the member states. In addition, according to the key facts published by the WHO, an estimated 300 million people are affected by depression, and 60 million people are affected by bipolar disorder, across the globe. Anxiety disorders are the most communal psychiatric illnesses affecting children and adults. It is evaluated that 44 million American grown-ups experience ill effects of uneasiness issue. Merely, about one-third of those suffering from an anxiety disorder receive treatment, even though the disorders are highly treatable. Therefore, it is indicated that the market is majorly driven by rise in prevalence of mental disorders.
The global antipsychotic drugs market is segmented into therapeutic class, application, distribution channel, and region. By therapeutic class, the market is categorized into first-generation and second-generation. By application, it is categorized into schizophrenia, dementia, bipolar disorder, depression and others. By distribution channel, it is divided into a hospital pharmacies, retail pharmacies, and online pharmacies.
Some of the major companies that operate in the global antipsychotic drugs market are Eli Lily and Company, AstraZeneca plc, GlaxoSmithKline plc, Johnson & Johnson, Otsuka Pharmaceutical Co, Ltd., Pfizer Inc., AbbVie Inc., Bristol-Myers Squibb, Teva Pharmaceuticals, and Dr. Reddy's Laboratories.
KEY BENEFITS FOR STAKEHOLDERS
• This report provides an extensive analysis of the current and emerging market trends and dynamics in the global antipsychotic drugs market to identify the prevailing opportunities.
• This study presents the competitive landscape of the global market to predict the competitive environment across geographies.
• Comprehensive analysis of factors that drive and restrict the market growth is provided.
• Region & country wise analysis is provided to understand the market trends and dynamics
KEY MARKET SEGMENTS
By Therapeutic Class
o First-generation
o Second-generation
By Application
o Schizophrenia
o Dementia
o Bipolar Disorder
o Depression
o Others
By Distribution Channel
o Hospital Pharmacies
o Retail Pharmacies
o Online Pharmacies
By Region
o North America
U.S.
Canada
Mexico
o Europe
Germany
France
UK
Italy
Spain
Rest of Europe
o Asia-Pacific
Japan
China
India
Australia
Rest of Asia-Pacific
o LAMEA
Brazil
South Africa
Saudi Arabia
Rest of LAMEA
KEY MARKET PLAYERS
• Eli Lily and Company
• AstraZeneca plc
• GlaxoSmithKline plc
• Johnson & Johnson
• Otsuka Pharmaceutical Co, Ltd.
• Pfizer Inc.
• AbbVie Inc.
• Bristol-Myers Squibb
• Teva Pharmaceuticals
• Dr. Reddy's Laboratories
1.1.Report description
1.2.Key benefits for stakeholders
1.3.Key market segments
1.4.Research methodology
1.4.1.Secondary research
1.4.2.Primary research
1.4.3.Analyst tools and models
CHAPTER 2:EXECUTIVE SUMMARY
2.1.Key findings of the study
2.2.CXO perspective
CHAPTER 3:MARKET OVERVIEW
3.1.Market definition and scope
3.2.Key findings
3.2.1.Top investment pockets
3.2.2.Top winning strategies
3.3.Porter’s five forces analysis
3.3.1.Top player positioning
3.4.Market dynamics
3.4.1.Drivers, restraints, and opportunities
3.4.2.Drivers
3.4.2.1.Rise in prevalence of mental health disorders
3.4.2.2.Increase in awareness of psychological disorders
3.4.3.Restraint
3.4.3.1.Side-effects of antipsychotic therapeutics
3.4.4.Opportunity
3.4.4.1.High growth potential in developing economies
3.5.Impact of COVID-19 on the antipsychotic drugs market
3.5.1.Overview
3.5.2.Impact analysis
CHAPTER 4:ANTIPSYCHOTIC DRUGS MARKET, BY THERAPEUTIC CLASS
4.1.Overview
4.1.1.Market size and forecast
4.2.First-generation
4.2.1.Key market trends and opportunities
4.2.2.Market size and forecast, by region
4.2.3.Market analysis, by country
4.3.Second-generation
4.3.1.Key market trends and opportunities
4.3.2.Market size and forecast, by region
4.3.3.Market analysis, by country
CHAPTER 5:ANTIPSYCHOTIC DRUGS MARKET, BY APPLICATION
5.1.Overview
5.1.1.Market size and forecast
5.2.Schizophrenia
5.2.1.Market size and forecast, by region
5.2.2.Market analysis, by country
5.3.Dementia
5.3.1.Market size and forecast, by region
5.3.2.Market analysis, by country
5.4.Bipolar disorder
5.4.1.Market size and forecast, by region
5.4.2.Market analysis, by country
5.5.Depression
5.5.1.Market size and forecast, by region
5.5.2.Market analysis, by country
5.6.Others
5.6.1.Market size and forecast, by region
5.6.2.Market analysis, by country
CHAPTER 6:ANTIPSYCHOTIC DRUGS MARKET, BY DISTRIBUTION CHANNEL
6.1.Overview
6.1.1.Market size and forecast
6.2.Hospital Pharmacies
6.2.1.Market size and forecast, by region
6.2.2.Market analysis, by country
6.2.2.1.Market size and forecast, by application
6.3.Retail Pharmacies
6.3.1.Market size and forecast, by region
6.3.2.Market analysis, by country
6.3.2.1.Market size and forecast, by application
6.4.Online Pharmacies
6.4.1.Market size and forecast, by region
6.4.2.Market analysis, by country
6.4.2.1.Market size and forecast, by application
CHAPTER 7:ANTIPSYCHOTIC DRUGS MARKET, BY REGION
7.1.Overview
7.1.1.Market size and forecast
7.2.North America
7.2.1.Key opportunities and forecast
7.2.2.Market size and forecast, by country
7.2.3.Market size and forecast, by therapeutic class
7.2.4.Market size and forecast, by application
7.2.5.Market size and forecast, by distribution channel
7.2.5.1.U.S.
7.2.5.1.1.U.S. market size and forecast, by therapeutic class
7.2.5.1.2.U.S. market size and forecast, by application
7.2.5.1.3.U.S. market size and forecast, by distribution channel
7.2.5.2.Canada
7.2.5.2.1.Canada market size and forecast, by therapeutic class
7.2.5.2.2.Canada market size and forecast, by application
7.2.5.2.3.Canada market size and forecast, by distribution channel
7.2.5.3.Mexico
7.2.5.3.1.Mexico market size and forecast, by therapeutic class
7.2.5.3.2.Mexico market size and forecast, by application
7.2.5.3.3.Mexico market size and forecast, by distribution channel
7.3.Europe
7.3.1.Key opportunities and forecast
7.3.2.Market size and forecast, by country
7.3.3.Market size and forecast, by therapeutic class
7.3.4.Market size and forecast, by application
7.3.5.Market size and forecast, by distribution channel
7.3.5.1.Germany
7.3.5.1.1.Germany market size and forecast, by therapeutic class
7.3.5.1.2.Germany market size and forecast, by application
7.3.5.1.3.Germany market size and forecast, by distribution channel
7.3.5.2.France
7.3.5.2.1.France market size and forecast, by therapeutic class
7.3.5.2.2.France market size and forecast, by application
7.3.5.2.3.France market size and forecast, by distribution channel
7.3.5.3.UK
7.3.5.3.1.UK market size and forecast, by therapeutic class
7.3.5.3.2.UK market size and forecast, by application
7.3.5.3.3.UK market size and forecast, by distribution channel
7.3.5.4.Italy
7.3.5.4.1.Italy market size and forecast, by therapeutic class
7.3.5.4.2.Italy market size and forecast, by application
7.3.5.4.3.Italy market size and forecast, by distribution channel
7.3.5.5.Spain
7.3.5.5.1.Spain market size and forecast, by therapeutic class
7.3.5.5.2.Spain market size and forecast, by application
7.3.5.5.3.Spain market size and forecast, by distribution channel
7.3.5.6.Rest of Europe
7.3.5.6.1.Rest of Europe market size and forecast, by therapeutic class
7.3.5.6.2.Rest of Europe market size and forecast, by application
7.3.5.6.3.Rest of Europe market size and forecast, by distribution channel
7.4.Asia-Pacific
7.4.1.Key opportunities and forecast
7.4.2.Market size and forecast, by country
7.4.3.Market size and forecast, by therapeutic class
7.4.4.Market size and forecast, by application
7.4.5.Market size and forecast, by distribution channel
7.4.5.1.Japan
7.4.5.1.1.Japan market size and forecast, by therapeutic class
7.4.5.1.2.Japan market size and forecast, by distribution channel
7.4.5.1.3.Japan market size and forecast, by distribution channel
7.4.5.2.China
7.4.5.2.1.China market size and forecast, by therapeutic class
7.4.5.2.2.China market size and forecast, by application
7.4.5.2.3.China market size and forecast, by distribution channel
7.4.5.3.Australia
7.4.5.3.1.Australia market size and forecast, by therapeutic class
7.4.5.3.2.Australia market size and forecast, by application
7.4.5.3.3.Australia market size and forecast, by distribution channel
7.4.5.4.India
7.4.5.4.1.India market size and forecast, by therapeutic class
7.4.5.4.2.India market size and forecast, by application
7.4.5.4.3.India market size and forecast, by distribution channel
7.4.5.5.South Korea
7.4.5.5.1.South Korea market size and forecast, by therapeutic class
7.4.5.5.2.South Korea market size and forecast, by application
7.4.5.5.3.South Korea market size and forecast, by distribution channel
7.4.5.6.Rest of Asia-Pacific
7.4.5.6.1.Rest of Asia-Pacific market size and forecast, by therapeutic class
7.4.5.6.2.Rest of Asia-Pacific market size and forecast, by application
7.4.5.6.3.Rest of Asia-Pacific market size and forecast, by distribution channel
7.5.LAMEA
7.5.1.Key opportunities and forecast
7.5.2.Market size and forecast, by country
7.5.3.Market size and forecast, by therapeutic class
7.5.4.Market size and forecast, by distribution channel
7.5.5.Market size and forecast, by distribution channel
7.5.5.1.Brazil
7.5.5.1.1.Brazil market size and forecast, by therapeutic class
7.5.5.1.2.Brazil market size and forecast, by application
7.5.5.1.3.Brazil market size and forecast, by distribution channel
7.5.5.2.Saudi Arabia
7.5.5.2.1.Saudi Arabia market size and forecast, by therapeutic class
7.5.5.2.2.Saudi Arabia market size and forecast, by application
7.5.5.2.3.Saudi Arabia market size and forecast, by distribution channel
7.5.5.3.South Africa
7.5.5.3.1.South Africa market size and forecast, by therapeutic class
7.5.5.3.2.South Africa market size and forecast, by application
7.5.5.3.3.South Africa market size and forecast, by distribution channel
7.5.5.4.Rest of LAMEA
7.5.5.4.1.Rest of LAMEA market size and forecast, by therapeutic class
7.5.5.4.2.Rest of LAMEA market size and forecast, by application
7.5.5.4.3.Rest of LAMEA market size and forecast, by distribution channel
CHAPTER 8:COMPANY PROFILES
8.1.ABBVIE INC. (ALLERGAN INC.)
8.1.1.Company overview
8.1.2.Company snapshot
8.1.3.Operating business segments
8.1.4.Product portfolio
8.1.5.Business performance
8.1.6.Key strategic moves and developments
8.2.ALKERMES PLC.
8.2.1.Company overview
8.2.2.Company snapshot
8.2.3.Operating business segments
8.2.4.Product portfolio
8.2.5.Business performance
8.2.6.Key strategic moves and developments
8.3.ASTRAZENECA PLC.
8.3.1.Company overview
8.3.2.Company snapshot
8.3.3.Operating business segments
8.3.4.Product portfolio
8.3.5.Business performance
8.4.BRISTOL-MYERS SQUIBB
8.4.1.Company overview
8.4.2.Company snapshot
8.4.3.Operating business segments
8.4.4.Product portfolio
8.4.5.Business performance
8.5.DR. REDDY’S LABORATORIES LIMITED
8.5.1.Company overview
8.5.2.Company snapshot
8.5.3.Operating business segments
8.5.4.Product portfolio
8.5.5.Business performance
8.5.6.Key strategic moves and developments
8.6.ELI LILLY AND COMPANY
8.6.1.Company overview
8.6.2.Company snapshot
8.6.3.Operating business segments
8.6.4.Product portfolio
8.6.5.Business performance
8.7.JOHNSON & JOHNSON (JANSSEN PHARMACEUTICALS)
8.7.1.Company overview
8.7.2.Company snapshot
8.7.3.Operating business segments
8.7.4.Product portfolio
8.7.5.Business performance
8.7.6.Key strategic moves and developments
8.8.OTSUKA HOLDINGS CO., LTD. (OTSUKA PHARMACEUTICAL CO., LTD.)
8.8.1.Company overview
8.8.2.Company snapshot
8.8.3.Operating business segments
8.8.4.Product portfolio
8.8.5.Business performance
8.8.6.Key strategic moves and developments
8.9.PFIZER INC.
8.9.1.Company overview
8.9.2.Company snapshot
8.9.3.Operating business segments
8.9.4.Product portfolio
8.9.5.Business performance
8.10.TEVA PHARMACEUTICAL INDUSTRIES LTD.
8.10.1.Company overview
8.10.2.Company snapshot
8.10.3.Operating business segments
8.10.4.Product portfolio
8.10.5.Business performance
TABLE 01.ANTIPSYCHOTIC DRUGS MARKET REVENUE, BY THERAPEUTIC CLASS, 2020–2030 ($MILLION)
TABLE 02.ANTIPSYCHOTIC DRUGS MARKET REVENUE FOR FIRST-GENERATION, BY REGION, 2020–2030($MILLION)
TABLE 03.ANTIPSYCHOTIC DRUGS MARKET REVENUE FOR SECOND-GENERATIONS, BY REGION, 2020–2028($MILLION)
TABLE 04.ANTIPSYCHOTIC DRUGS MARKET REVENUE, BY APPLICATION, 2020–2030 ($MILLION)
TABLE 05.ANTIPSYCHOTIC DRUGS MARKET REVENUE FOR SCHIZOPHRENIA, BY REGION, 2020–2030($MILLION)
TABLE 06.ANTIPSYCHOTIC DRUGS MARKET REVENUE FOR DEMENTIA, BY REGION, 2020–2028($MILLION)
TABLE 07.ANTIPSYCHOTIC DRUGS MARKET REVENUE FOR BIPOLAR DISORDER, BY REGION, 2020–2030($MILLION)
TABLE 08.ANTIPSYCHOTIC DRUGS MARKET REVENUE FOR DEPRESSION, BY REGION, 2020–2030 ($MILLION)
TABLE 09.ANTIPSYCHOTIC DRUGS MARKET REVENUE FOR OTHERS, BY REGION, 2020–2030 ($MILLION)
TABLE 10.ANTIPSYCHOTIC DRUGS MARKET REVENUE, BY DISTRIBUTION CHANNEL, 2020–2030($MILLION)
TABLE 11.HOSPITAL PHARMACIES FOR ANTIPSYCHOTIC DRUGS MARKET REVENUE, BY REGION, 2020–2030($MILLION)
TABLE 12.HOSPITAL PHARMACIES FOR ANTIPSYCHOTIC DRUGS MARKET REVENUE, BY APPLICATION, 2020–2030($MILLION)
TABLE 13.RETAIL PHARMACIES FOR ANTIPSYCHOTIC DRUGS MARKET REVENUE, BY REGION, 2020–2030 ($MILLION)
TABLE 14.RETAIL PHARMACIES FOR ANTIPSYCHOTIC DRUGS MARKET REVENUE, BY APPLICATION, 2020–2030($MILLION)
TABLE 15.ONLINE PHARMACIES FOR ANTIPSYCHOTIC DRUGS MARKET REVENUE, BY REGION, 2020–2030 ($MILLION)
TABLE 16.ONLINE PHARMACIES FOR ANTIPSYCHOTIC DRUGS MARKET REVENUE, BY APPLICATION, 2020–2030($MILLION)
TABLE 17.ANTIPSYCHOTIC DRUGS MARKET, BY REGION, 2020–2030($MILLION)
TABLE 18.NORTH AMERICA ANTIPSYCHOTIC DRUGS MARKET, BY COUNTRY, 2020–2030($MILLION)
TABLE 19.NORTH AMERICA ANTIPSYCHOTIC DRUGS MARKET, BY THERAPEUTIC CLASS, 2020–2030($MILLION)
TABLE 20.NORTH AMERICA ANTIPSYCHOTIC DRUGS MARKET, BY APPLICATION CHANNEL, 2020–2030($MILLION)
TABLE 21.NORTH AMERICA ANTIPSYCHOTIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2020–2030($MILLION)
TABLE 22.U.S. ANTIPSYCHOTIC DRUGS MARKET, BY THERAPEUTIC CLASS, 2020–2030($MILLION)
TABLE 23.U.S. ANTIPSYCHOTIC DRUGS MARKET, BY APPLICATION, 2020–2030($MILLION)
TABLE 24.U.S. ANTIPSYCHOTIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2020–2030($MILLION)
TABLE 25.CANADA ANTIPSYCHOTIC DRUGS MARKET, BY THERAPEUTIC CLASS, 2020–2030($MILLION)
TABLE 26.CANADA ANTIPSYCHOTIC DRUGS MARKET, BY APPLICATION, 2020–2030($MILLION)
TABLE 27.CANADA ANTIPSYCHOTIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2020–2030($MILLION)
TABLE 28.MEXICO ANTIPSYCHOTIC DRUGS MARKET, BY THERAPEUTIC CLASS, 2020–2030($MILLION)
TABLE 29.MEXICO ANTIPSYCHOTIC DRUGS MARKET, BY APPLICATION, 2020–2030($MILLION)
TABLE 30.MEXICO ANTIPSYCHOTIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2020–2030($MILLION)
TABLE 31.EUROPE ANTIPSYCHOTIC DRUGS MARKET, BY COUNTRY, 2020–2030($MILLION)
TABLE 32.EUROPE ANTIPSYCHOTIC DRUGS MARKET, BY THERAPEUTIC CLASS, 2020–2030($MILLION)
TABLE 33.EUROPE ANTIPSYCHOTIC DRUGS MARKET, BY APPLICATION, 2020–2030($MILLION)
TABLE 34.EUROPE ANTIPSYCHOTIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2020–2030($MILLION)
TABLE 35.GERMANY ANTIPSYCHOTIC DRUGS MARKET, BY THERAPEUTIC CLASS, 2020–2030($MILLION)
TABLE 36.GERMANY ANTIPSYCHOTIC DRUGS MARKET, BY APPLICATION, 2020–2030($MILLION)
TABLE 37.GERMANY ANTIPSYCHOTIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2020–2030($MILLION)
TABLE 38.FRANCE ANTIPSYCHOTIC DRUGS MARKET, BY THERAPEUTIC CLASS, 2020–2030($MILLION)
TABLE 39.FRANCE ANTIPSYCHOTIC DRUGS MARKET, BY APPLICATION, 2020–2030($MILLION)
TABLE 40.FRANCE ANTIPSYCHOTIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2020–2030($MILLION)
TABLE 41.UK ANTIPSYCHOTIC DRUGS MARKET, BY THERAPEUTIC CLASS, 2020–2030($MILLION)
TABLE 42.UK ANTIPSYCHOTIC DRUGS MARKET, BY APPLICATION, 2020–2030($MILLION)
TABLE 43.UK ANTIPSYCHOTIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2020–2030($MILLION)
TABLE 44.ITALY ANTIPSYCHOTIC DRUGS MARKET, BY THERAPEUTIC CLASS, 2020–2030($MILLION)
TABLE 45.ITALY ANTIPSYCHOTIC DRUGS MARKET, BY APPLICATION, 2020–2030($MILLION)
TABLE 46.ITALY ANTIPSYCHOTIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2020–2030($MILLION)
TABLE 47.SPAIN ANTIPSYCHOTIC DRUGS MARKET, BY THERAPEUTIC CLASS, 2020–2030($MILLION)
TABLE 48.SPAIN ANTIPSYCHOTIC DRUGS MARKET, BY APPLICATION, 2020–2030($MILLION)
TABLE 49.SPAIN ANTIPSYCHOTIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2020–2030($MILLION)
TABLE 50.REST OF EUROPE ANTIPSYCHOTIC DRUGS MARKET, BY THERAPEUTIC CLASS, 2020–2030($MILLION)
TABLE 51.REST OF EUROPE ANTIPSYCHOTIC DRUGS MARKET, BY APPLICATION, 2020–2030($MILLION)
TABLE 52.REST OF EUROPE ANTIPSYCHOTIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2020–2030($MILLION)
TABLE 53.ASIA-PACIFIC ANTIPSYCHOTIC DRUGS MARKET, BY COUNTRY, 2020–2030($MILLION)
TABLE 54.ASIA-PACIFIC ANTIPSYCHOTIC DRUGS MARKET, BY THERAPEUTIC CLASS, 2020–2030($MILLION)
TABLE 55.ASIA-PACIFIC ANTIPSYCHOTIC DRUGS MARKET, BY APPLICATION, 2020–2030($MILLION)
TABLE 56.ASIA-PACIFIC ANTIPSYCHOTIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2020–2030($MILLION)
TABLE 57.JAPAN ANTIPSYCHOTIC DRUGS MARKET, BY THERAPEUTIC CLASS, 2020–2030($MILLION)
TABLE 58.JAPAN ANTIPSYCHOTIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2020–2030($MILLION)
TABLE 59.JAPAN ANTIPSYCHOTIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2020–2030($MILLION)
TABLE 60.CHINA ANTIPSYCHOTIC DRUGS MARKET, BY THERAPEUTIC CLASS, 2020–2030($MILLION)
TABLE 61.CHINA ANTIPSYCHOTIC DRUGS MARKET, BY APPLICATION, 2020–2030($MILLION)
TABLE 62.CHINA ANTIPSYCHOTIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2020–2030($MILLION)
TABLE 63.AUSTRALIA ANTIPSYCHOTIC DRUGS MARKET, BY THERAPEUTIC CLASS, 2020–2030($MILLION)
TABLE 64.AUSTRALIA ANTIPSYCHOTIC DRUGS MARKET, BY APPLICATION, 2020–2030($MILLION)
TABLE 65.AUSTRALIA ANTIPSYCHOTIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2020–2030($MILLION)
TABLE 66.INDIA ANTIPSYCHOTIC DRUGS MARKET, BY THERAPEUTIC CLASS, 2020–2030($MILLION)
TABLE 67.INDIA ANTIPSYCHOTIC DRUGS MARKET, BY APPLICATION, 2020–2030($MILLION)
TABLE 68.INDIA ANTIPSYCHOTIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2020–2030($MILLION)
TABLE 69.SOUTH KOREA ANTIPSYCHOTIC DRUGS MARKET, BY THERAPEUTIC CLASS, 2020–2030($MILLION)
TABLE 70.SOUTH KOREA ANTIPSYCHOTIC DRUGS MARKET, BY APPLICATION, 2020–2030($MILLION)
TABLE 71.SOUTH KOREA ANTIPSYCHOTIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2020–2030($MILLION)
TABLE 72.REST OF ASIA-PACIFIC ANTIPSYCHOTIC DRUGS MARKET, BY THERAPEUTIC CLASS, 2020–2030($MILLION)
TABLE 73.REST OF ASIA-PACIFC ANTIPSYCHOTIC DRUGS MARKET, BY APPLICATION, 2020–2030($MILLION)
TABLE 74.REST OF ASIA-PACIFC ANTIPSYCHOTIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2020–2030($MILLION)
TABLE 75.LAMEA ANTIPSYCHOTIC DRUGS MARKET, BY COUNTRY, 2020–2030($MILLION)
TABLE 76.LAMEA ANTIPSYCHOTIC DRUGS MARKET, BY THERAPEUTIC CLASS, 2020–2030($MILLION)
TABLE 77.LAMEA ANTIPSYCHOTIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2020–2030($MILLION)
TABLE 78.LAMEA ANTIPSYCHOTIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2020–2030($MILLION)
TABLE 79.BRAZIL ANTIPSYCHOTIC DRUGS MARKET, BY THERAPEUTIC CLASS, 2020–2030($MILLION)
TABLE 80.BRAZIL ANTIPSYCHOTIC DRUGS MARKET, BY APPLICATION, 2020–2030($MILLION)
TABLE 81.BRAZIL ANTIPSYCHOTIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2020–2030($MILLION)
TABLE 82.SAUDI ARABIA ANTIPSYCHOTIC DRUGS MARKET, BY THERAPEUTIC CLASS, 2020–2030($MILLION)
TABLE 83.SAUDI ARABIA ANTIPSYCHOTIC DRUGS MARKET, BY APPLICATION, 2020–2030($MILLION)
TABLE 84.SAUDI ARABIA ANTIPSYCHOTIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2020–2030($MILLION)
TABLE 85.SOUTH AFRICA ANTIPSYCHOTIC DRUGS MARKET, BY THERAPEUTIC CLASS, 2020–2030($MILLION)
TABLE 86.SOUTH AFRICA ANTIPSYCHOTIC DRUGS MARKET, BY APPLICATION, 2020–2030($MILLION)
TABLE 87.SOUTH AFRICA ANTIPSYCHOTIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2020–2030($MILLION)
TABLE 88.REST OF LAMEA ANTIPSYCHOTIC DRUGS MARKET, BY THERAPEUTIC CLASS, 2020–2030($MILLION)
TABLE 89.REST OF LAMEA ANTIPSYCHOTIC DRUGS MARKET, BY APPLICATION, 2020–2030($MILLION)
TABLE 90.REST OF LAMEA ANTIPSYCHOTIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2020–2030($MILLION)
TABLE 91.ABBVIE: COMPANY SNAPSHOT
TABLE 92.ABBVIE: PRODUCT SEGMENTS
TABLE 93.ABBVIE: PRODUCT PORTFOLIO
TABLE 94.ABBVIE: KEY DEVELOPMENTS
TABLE 95.ALKERMES: COMPANY SNAPSHOT
TABLE 96.ALKERMES: PRODUCT SEGMENTS
TABLE 97.ALKERMES: PRODUCT PORTFOLIO
TABLE 98.ALKERMES: KEY DEVELOPMENTS
TABLE 99.ASTRAZENECA: COMPANY SNAPSHOT
TABLE 100.ASTRAZENECA: OPERATING SEGMENTS
TABLE 101.ASTRAZENECA: PRODUCT PORTFOLIO
TABLE 102.BRISTOL: COMPANY SNAPSHOT
TABLE 103.BRISTOL: PRODUCT SEGMENTS
TABLE 104.BRISTOL: PRODUCT PORTFOLIO
TABLE 105.REDDY: COMPANY SNAPSHOT
TABLE 106.REDDY: OPERATING BUSINESS SEGMENTS
TABLE 107.REDDY: PRODUCT PORTFOLIO
TABLE 108.REDDY: KEY DEVELOPMENTS
TABLE 109.LILLY: COMPANY SNAPSHOT
TABLE 110.LILLY: OPERATING SEGMENTS
TABLE 111.LILLY: PRODUCT PORTFOLIO
TABLE 112.JOHNSON: COMPANY SNAPSHOT
TABLE 113.JOHNSON: PRODUCT SEGMENTS
TABLE 114.JOHNSON: PRODUCT PORTFOLIO
TABLE 115.JOHNSON: KEY DEVELOPMENTS
TABLE 116.OTSUKA: COMPANY SNAPSHOT
TABLE 117.OTSUKA: OPERATING SEGMENTS
TABLE 118.OTSUKA: PRODUCT PORTFOLIO
TABLE 119.OTSUKA: KEY DEVELOPMENTS
TABLE 120.PFIZER: COMPANY SNAPSHOT
TABLE 121.PFIZER: OPERATING BUSINESS SEGMENTS
TABLE 122.PFIZER: PRODUCT PORTFOLIO
TABLE 123.TEVA: COMPANY SNAPSHOT
TABLE 124.TEVA: OPERATING SEGMENTS
TABLE 125.TEVA: PRODUCT PORTFOLIO
Similar Reports
Complete report $6,100. DataPack (test volumes, sales forecasts, supplier shares) $3,950.
Summary
This comprehensive report contains 409 pages, 35 tables, and is designed to help current suppliers and potential market entrants identify and evaluate business opportunities emerging in the UK coagulation testing market duri...
- Publish Date: February 7, 2017
- $750
Complete report $9,600. DataPack (test volumes, sales forecasts, supplier shares) $6,200.
Summary
This comprehensive report contains 424 pages, 37 tables, and is designed to help current suppliers and potential market entrants identify and evaluate business opportunities emerging in the US coagulation testing market during the...
- Publish Date: February 7, 2017
- $750
This new report from VPGMarketResearch.com provides strategic assessments of major blood banking product suppliers and emerging market entrants. The report presents analyses of major current and emerging suppliers in terms of their sales, market shares, product portfolios, marketing tactics, technological know-how, new products in R&D, collaborative arrangements, and business strategies.
Con...
- Publish Date: February 7, 2017
- $750
